|
|
|
| Development of a HPV16 E7 CTLs Peptides-based Virus-like Particle Therapeutic Vaccine |
| CHU Xiao-jie1,2,3, LI Yang1,2,3, LONG Qiong1,2,3, YAO Yu-feng1,2,3, SUN Wen-jia1,2,3, HUANG Wei-wei1,2,3, YANG Xu1,2,3, Liu Cun-bao1,2,3, MA Yan-bing1,2,3 |
1. Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming 650118, China;
2. Yunnan Key Laboratory of Vaccine Research&Development on Severe Infectious Disease, Kunming 650118, China;
3. Yunnan Engineering Research Center of Vaccine Research and Development on Severe Infectious Disease, Kunming 650118, China |
|
|
|
Abstract Objective: To construct virus-like particles (VLPs) presenting CTLs epitopes of HPV16 E7, and assess its potentials to be an effective form of therapeutic vaccine. Methods: Three reported effective HPV16 E7 CTLs epitopes were selected and used to be presented by HBcAg VLPs. The oligonucleotides encoding for the three peptides were synthesized and inserted respectively into the plasmid pThioHisA-HBcAg. The recombinant plasmids were tansformed into DH5α cells, and the expression of the chimeric proteins were induced with IPTG and identified by SDS-PAGE. The proteins were purified with a procedure consists of ammonium sulfate precipitation and sucrose density gradient centrifugation, and the presence of VLPs was detected with HPLC of size-exclusion chromatography and electron microscopy. Mice received TC-1 graft were immunized with the mixed VLPs, and the dynamic changes of tumor size were recorded. In addition, the splenocytes isolated from the experimental mice were stimulated in vitro with the synthetic antigenic peptides and the expression of IFN-γ was measured by ELISA. Results: Three constructed recombinant plasmids were proven to be correct by restriction enzyme digestion and DNA sequencing. The recombinant proteins were expressed efficiently, and presented as VLPs. Tumor growth was suppressed in vaccinated mice. Furthermore, the IFN-γ expression of splenocytes was promoted by the stimulation of antigenic peptides, indicating that the VLPs caused the E7-specific cellular immune response. Conclusion: Presenting HPV E7 CTLs epitopes with HBcAg VLPs is a potential strategy for developing an effective therapeutic HPV vaccine.
|
|
Received: 26 November 2014
Published: 25 February 2015
|
|
|
|
Cite this article:
CHU Xiao-jie, LI Yang, LONG Qiong, YAO Yu-feng, SUN Wen-jia, HUANG Wei-wei, YANG Xu, Liu Cun-bao, MA Yan-bing. Development of a HPV16 E7 CTLs Peptides-based Virus-like Particle Therapeutic Vaccine. China Biotechnology, 2015, 35(2): 45-51.
URL:
https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20150207 OR https://manu60.magtech.com.cn/biotech/Y2015/V35/I2/45
|
|
|
|
[1] Parkin D M, Bray F, Ferlay J, et al.Global cancer statistics, 2002.CA Cancer J Clin,2005,55(2): 74-108.
[2] Bolhassani A, Mohit E, Rafati S.Different spectra of therapeutic vaccine development against HPV infections.Hum Vaccin,2009,5(10): 671-689.
[3] Niebler M, Qian X, Hofler D, et al.Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53.PLoS Pathog,2013,9(8): e1003536.
[4] Yu Y, Munger K.Human papillomavirus type 16 E7 oncoprotein inhibits the anaphase promoting complex/cyclosome activity by dysregulating EMI1 expression in mitosis.Virology,2013,446(1-2): 251-259.
[5] Jemon K, Young V, Wilson M, et al.An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.PLoS One,2013,8(6): e66866.
[6] Monroy-Garcia A, Gomez-Lim M A, Weiss-Steider B, et al.Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.Arch Virol,2014,159(2): 291-305.
[7] Pokorna D, Polakova I, Kindlova M, et al.Vaccination with human papillomavirus type 16-derived peptides using a tattoo device.Vaccine,2009,27(27): 3519-3529.
[8] Ressing M E, van Driel W J, Brandt R M, et al.Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.J Immunother,2000,23(2): 255-266.
[9] Berzofsky J A, Ahlers J D, Janik J, et al.Progress on new vaccine strategies against chronic viral infections.J Clin Invest,2004,114(4): 450-462.
[10] Bolhassani A,Mohit E,Rafati S.Different spectra of therapeutic vaccine development against HPV infections.Hum Vaccin,2009,5(10):671-689.
[11] Schreurs M W, Kueter E W, Scholten K B, et al.A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope.Vaccine,2005,23(31):4005-4010.
[12] Song Y C, Cheng H Y, Leng C H, et al.A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity.J Control Release,2014,173: 158-165.
[13] Klencke B, Matijevic M, Urban R G, et al.Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.Clin Cancer Res,2002,8(5):1028-1037.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
